Articles tagged with Alzheimer Disease
A new study reveals that presenilin works with enzyme GSK-3ß to control material transport through neurons. Low levels of presenilin or high levels of GSK-3ß can cause uncoordinated movement, resulting in dangerous blockages. Researchers propose a potential pathway for early intervention through drugs.
Researchers have identified specific molecules called microRNAs that regulate both good and bad protein levels in the brain. Targeting these molecules may help preserve brain function and detect Alzheimer's disease at an earlier age.
Researchers identified 11 new genes associated with late-onset Alzheimer's disease, including SORL1 and CASS4, which affect amyloid and tau protein accumulation. The study also found connections between these genes and inflammation, synaptic function, and brain cell activity.
Researchers discovered 11 new regions of the genome that contribute to late-onset Alzheimer's disease, doubling the number of potential genetics-based therapeutic targets. The study also identified a genetic overlap with other neurodegenerative diseases, including multiple sclerosis and Parkinson's disease.
The I-GAP consortium has identified 11 new regions of the genome involved in Alzheimer's disease, providing insights into its molecular mechanisms. These findings confirm biological pathways and immune response involvement, opening avenues to understanding the causes of AD.
A global collaboration of researchers has identified 11 new genetic areas of interest contributing to late onset Alzheimer's Disease. The study expands the scope of disease understanding to include new areas such as the immune system, where a genetic overlap with other neurodegenerative diseases was found.
Researchers at UAB designed an antibody fragment that cleared Aβ peptide oligomers from the cerebral cortex, reversing anxiety and learning memory deficits in mice. The treatment also improved apolipoprotein levels, suggesting a potential therapeutic approach for Alzheimer's disease.
A study led by Dr. Pasinetti found that diabetes alters gene expression in the brain, reducing important molecules critical for learning and memory. This epigenetic change increases the risk of developing Alzheimer's disease.
Researchers at Linköping University have identified six proteins in spinal fluid that can be used as markers for the illness, offering a potential step towards early diagnosis. The study found that these proteins are associated with the breakdown of brain cells and toxic accumulations of beta amyloid protein.
A new study found that reports of shorter sleep duration and poorer sleep quality in older adults are associated with higher levels of beta-amyloid buildup, a hallmark of Alzheimer's disease. The study suggests that treatments for poor sleep may help prevent or slow the progression of the disease.
A Yale School of Medicine study found that immune sensor Nlrp3 inflammasome triggers age-related inflammation, leading to loss of function and frailty. Reducing Nlrp3 activation may help delay or prevent chronic diseases.
Researchers at the Buck Institute discovered a link between ApoE4 and SirT1, an anti-aging protein targeted by resveratrol. Increasing SirT1 may prevent Alzheimer's disease-related abnormalities in brain samples from patients with ApoE4 and AD.
A study of 70 elderly adults found that shorter sleep duration and poorer sleep quality were associated with greater beta-amyloid buildup in the brain, a hallmark of Alzheimer's disease. The research suggests that optimizing sleep may help prevent or slow AD progression.
A recent study published in Science shows that the brain's unique glymphatic system, responsible for removing waste, is highly active during sleep. This process clears away toxic proteins associated with Alzheimer's disease, suggesting a vital function of sleep in maintaining brain health.
The UCI's 90+ Study, a five-year research project focused on the health and lifestyle issues of Americans in their 90s or older, has received renewed funding. Researchers plan to use PET and MRI scans to investigate factors associated with Alzheimer's disease and dementia, as well as monitor blood pressure and oxygen saturation.
A new study from the University of Southern California has found that a genetic mutation associated with Alzheimer's disease can double the rate of brain tissue loss. This means that individuals carrying this mutation may experience symptoms earlier than expected, highlighting the need for targeted clinical studies and treatments.
A study published in Neurology found that elderly individuals with hardening of the arteries are more likely to have beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. The study also showed that increased arterial stiffness was associated with a higher risk of developing dementia.
Researchers measured levels of proteins in cerebrospinal fluid to predict cognitive impairment, identifying biomarkers that signal potential development of Alzheimer's disease up to five years before symptom onset. The study offers a potential tool for guiding earlier use of treatments and testing new drugs.
A Johns Hopkins-led analysis suggests that taking certain blood pressure medications may reduce the risk of dementia due to Alzheimer's disease by at least 50 percent. The study found that diuretics and ACE inhibitors were associated with a reduced risk in people over 75 with normal cognition.
A Mayo Clinic study reveals that individuals with speech and language disorders are 3.5 times more likely to be teachers, highlighting an occupational hazard for educators. The researchers also found no such correlation between other occupations and the development of these disorders.
Researchers have identified a protective pathway that helps counteract the toxicity associated with Alzheimer's disease. By preventing amyloid-β peptides from interacting with prion protein, stress-inducible phosphoprotein 1 (STI1) protects neurons from damage.
Research confirms GWI deficits in working memory, a critical cognitive function that enables short-term retention of information. Brain alterations reveal a unique neurobiological marker that could positively identify GWI, with potential implications for Alzheimer's disease treatment.
Researchers found that epigenetic changes in the brain are associated with Alzheimer's disease, offering potential for novel diagnostic and therapeutic strategies. Epigenetic markers such as DNA methylation and hydroxymethylation increased with age, correlating with AD pathology.
A Vanderbilt study found that 74% of patients with respiratory failure, cardiogenic shock, or septic shock developed delirium in the hospital, leading to dementia-like brain disease even a year after discharge. Cognitive deficits persisted for up to 12 months in both older and younger patients.
Scientists at University of Wisconsin-Madison discover that zinc ions play a crucial role in maintaining protein stability. A shortage of zinc can cause proteins to misfold and clump together, leading to cell death. Researchers identify a 'protein chaperone' called Tsa1 that prevents protein aggregation and maintains cellular balance.
Researchers have discovered anti-tau antibodies that can prevent the accumulation of toxic tau proteins, improving cognitive function and reducing pathology in mouse models. The findings suggest a potential basis for treating Alzheimer's disease and other neurodegenerative disorders.
Researchers identify two rare gene mutations that increase generation and accumulation of toxic amyloid beta protein, impairing neural cell growth. The findings suggest the enzyme ADAM10 as a promising therapeutic target for treatment and prevention.
Scientists validate a proposed system for detecting preclinical Alzheimer's disease in cognitively normal elderly individuals, finding that it is common and associated with future mental decline and mortality. The new findings offer reason for encouragement, showing that the system can predict which individuals will develop symptoms of...
Researchers found that patients diagnosed with early Alzheimer's disease who received brain imaging test results had better clinical outcomes, including superior executive function and memory abilities. The study suggests that earlier diagnosis can lead to significant benefits, potentially saving healthcare dollars.
A new research chair will focus on developing innovative strategies for preventing and treating Alzheimer's disease, including early detection tools and less toxic therapeutic molecules. The goal is to improve patient quality of life and alleviate symptoms rather than control the disease.
Researchers at the DZNE and Charité-Universitätsmedizin Berlin have discovered a gradient of inhibition within the entorhinal cortex, which may play a crucial role in creating synchronous rhythms and oscillations. This finding has implications for understanding Alzheimer's disease, where the entorhinal cortex is affected early on.
Researchers found that a class of proteins affecting visual system development also appears to affect vulnerability to Alzheimer's disease in the aging brain. The proteins, such as LilrB2 and PirB, physically partner with beta-amyloid, triggering a harmful chain reaction in brain cells.
Researchers discovered that beta-amyloid destroys synapses by binding to a receptor called PirB, leading to a cascade of biochemical activities. The study suggests that Alzheimer's disease starts to manifest long before plaque formation becomes evident, offering new hope for earlier treatments.
A new clinical trial has launched, aiming to prevent Alzheimer's disease by giving new drug treatments before dementia symptoms appear. The trial, led by principal investigator Randall Bateman, is testing two innovative treatments and has been made possible through a unique collaboration of private and public resources.
Researchers developed a new class of imaging agents to visualize tau protein aggregates, a hallmark of Alzheimer's disease. The use of these fluorescent compounds in PET tests provides valuable information on brain regions at risk for tau-induced neuronal death.
Researchers have identified distinct molecular structures of beta-amyloid fibrils in Alzheimer's disease brains, which correlate with individual patient outcomes. These findings hold promise for developing patient-specific diagnostic imaging agents and treatments tailored to specific fibril structures.
Researchers at Emory University have discovered a previously unrecognized type of pathology in Alzheimer's brains that sequesters proteins involved in RNA splicing. This finding could lead to new biomarkers, diagnostic approaches, and therapies by explaining how genes contribute their effects in the disease.
Prostratin and bryostatin show promise as effective treatments for HIV/AIDS, Alzheimer's disease, and resistant cancer. Prostratin flushes out HIV from its cellular sanctuaries, while analogs of bryostatin are up to 1,000-fold more potent in doing so.
Researchers discovered that degeneration of the fornix, a structure carrying messages to and from the hippocampus, is a key predictor of future cognitive decline. Fornix variables were found to precede clinically relevant deterioration of cognitive function in cognitively normal elderly individuals.
Two neurology researchers propose that prion-like protein aggregates drive multiple brain diseases associated with aging. These seeds disrupt nervous system function and can stimulate the aggregation of other proteins, suggesting therapeutic strategies to combat these diseases.
Researchers found that amyloid beta stimulates Alpha7 nicotinic receptors, triggering astrocytes to release glutamate and overwhelming synapses. A newly modified Alzheimer's drug may block this destructive pathway.
Researchers at Yale University have identified a protein that serves as the missing link in the chain of events leading to Alzheimer's disease. Blocking this protein with an existing drug has been shown to restore memory and synaptic density in mouse models of the disease. The findings offer strong hope for developing new treatments.
Researchers discovered a defect in microglia's internal recycling program, leading to faulty phagocytosis and accumulation of A-beta protein. This impairment may contribute to the development of Alzheimer's disease by allowing toxic substances to remain in the brain.
A University of South Florida-led study suggests that the stress-related protein FKBP51 contributes to the acceleration of Alzheimer's disease. The research found that FKBP51 levels increase with age and partner with Hsp90 to make tau more toxic, leading to brain cell death.
Researchers have identified a promising avenue for early diagnosis of Alzheimer's disease through non-invasive brain wave analysis. The study found statistically significant differences in brain wave patterns between healthy individuals and those with mild to moderate Alzheimer's disease.
A study at Columbia University Irving Medical Center identifies RbAp48 as a significant contributor to age-related memory loss, which can be reversed. The researchers found that RbAp48 plays an active role in the process and propose it as a target for therapeutic intervention.
A genome-wide survey has identified a significant association between regions of homozygosity (ROHs) and the etiology of Alzheimer disease in Caribbean Hispanics. The study found that ROHs could significantly contribute to AD in this population, with notable associations observed at specific genetic loci.
Researchers analyzed anatomical connectivity in the brains of subjects with Alzheimer's disease and healthy older individuals, finding widespread network disruptions. The study also identified asymmetry in the proportions of fibers connecting left and right cortical regions, which may worsen as the disease progresses.
A survey of 139 Alzheimer's clinical trial leaders found that a majority supported disclosing test results to study participants, citing the need for guidance and counseling. The study suggests that as biomarkers improve, experts want to share valid results with participants, while also addressing potential harms and benefits.
Researchers found that AD mouse models with neurodegeneration have 25% more copper in their amyloid plaques than those without, suggesting altered copper regulation may contribute to neurotoxicity. Iron levels were also increased, particularly in the ferric state, and may serve as a biomarker for early-stage AD.
A study found that copper accelerates the pathology of Alzheimer's disease by disrupting the removal of amyloid beta from the brain and stimulating its production. Copper accumulation can lead to inflammation and breakdown of the blood-brain barrier, promoting toxic protein buildup.
A study published in JAMA Neurology reveals that disruptions in brain networks emerge simultaneously with chemical markers of early Alzheimer's disease. The research provides an effective and less invasive way to detect early disease, potentially improving treatment outcomes.
A study found that decreased Aß42 and increased phosphorylated tau181 levels in spinal fluid are linked to reduced default mode network integrity. This association suggests that these biomarkers could be used to detect Alzheimer's disease pathology before symptoms appear.
Researchers have discovered a new therapeutic target for Alzheimer's disease, which regulates N-methyl-D-aspartate receptor transport. Valeric acid, an N-methyl-D-aspartate receptor antagonist, has been shown to significantly inhibit the progression of learning and memory disturbances induced by Alzheimer's disease.
A study identified a potential biomarker for Alzheimer's disease in cerebral spinal fluid, suggesting the condition may be detectable a decade before symptoms appear. Researchers hope to find treatments that can prevent or slow the progression of the disease.
Researchers developed a new test to identify early-onset dementia in individuals aged 40-65 using face recognition tests, distinguishing between name and facial recognition. The study found significant differences in brain tissue loss between those with and without dementia, providing valuable insights into cognitive impairment.
Researchers have identified a modification to the protein eIF2alpha linked to Alzheimer's-like conditions, which may lead to decreased protein synthesis and impaired long-term memories. Abnormal levels of phosphorylation were found in AD model mice and postmortem human patients, highlighting potential therapeutic targets.
Researchers analyzed data from over 30,000 patients to determine if Parkinson's disease and Alzheimer's disease share a common genetic risk factor. The study found no evidence of such overlap.
New study links aluminum accumulation to neuronal cell death and identifies necrostatin-1 as a substance that counteracts aluminum's neurotoxic effects. In mice treated with aluminum, Nec-1 demonstrated strong protection against cell death and improved cognitive function.
Researchers have developed two new classes of compounds that target the gamma-secretase enzyme to treat Alzheimer's disease. These compounds produce shorter forms of amyloid peptide 38, which do not aggregate into neurotoxic plaques. Early-onset hereditary forms of Alzheimer's may be linked to mutations in the APP protein gene, leading...